Evidence map›Paper›PMID 30801785›Full record

ArticleEuropean journal of haematology2019

Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.

Il-Kang Na, Matthew Buckland, Carlo Agostini, John David M Edgar, Vanda Friman, Mauricette Michallet, Silvia Sánchez-Ramón, Carmen Scheibenbogen, Isabella Quinti

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Il-Kang NaDepartment of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Matthew BucklandUCL Centre for Immunodeficiency, Royal Free Hospital and Great Ormond Street Hospital NHS Foundation Trusts, London, UK.
Carlo AgostiniDepartment of Internal Medicine, University Hospital, Padua University, Treviso, Italy.
John David M EdgarRegional Immunology Service, The Royal Hospitals, Belfast, UK.
Vanda FrimanDepartment of Infectious Diseases, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Mauricette MichalletUniversité Claude Bernard Lyon, Lyon, France.
Silvia Sánchez-RamónDepartamento de Inmunología Clínica, Hospital Clínico San Carlos, Universidad Complutense of Madrid, Spain.
Carmen ScheibenbogenInstitute for Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität (FU) Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Isabella QuintiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Freie Universität Berlin · DECentre Léon Bérard · FRHospital Clínico San Carlos · ESSapienza University of Rome · ITUniversity College London · GBUniversity of Gothenburg · SEUniversity of Padua · ITUniversity of Ulster · GB

Funding

Octapharma
6 · The paper itself

Abstract

objectiveDespite long-standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B-cell lymphoproliferative diseases are limited. Here, we examine the correlation between approved IgRT indications, treatment recommendations, and clinical practice in SID.

methodsAn international online survey of 230 physicians responsible for the diagnosis of SID and the prescription of IgRT in patients with hematological malignancies was conducted.

resultsSerum immunoglobulin was measured in 83% of patients with multiple myeloma, 76% with chronic lymphocytic leukemia, and 69% with non-Hodgkin lymphoma. Most physicians (85%) prescribed IgRT after ≥2 severe infections. In Italy, Germany, Spain, and the United States, immunoglobulin use was above average in patients with hypogammaglobulinemia, while in the UK considerably fewer patients received IgRT. The use of subcutaneous immunoglobulin was highest in France (34%) and lowest in Spain (19%). Immunologists measured specific antibody responses, performed test immunization, implemented IgRT, and used subcutaneous immunoglobulin more frequently than physicians overall.

conclusionsThe management of SID in hematological malignancies varied regionally. Clinical practice did not reflect treatment guidelines, highlighting the need for robust clinical studies on IgRT in this population and harmonization between countries and disciplines.

Indexed as

Disease ManagementGlobal HealthHematologic NeoplasmsHumansImmunoglobulinsImmunoglobulins, IntravenousImmunologic Deficiency SyndromesInfection ControlInfectionsPublic Health SurveillanceTreatment OutcomeImmunoglobulinsImmunoglobulins, Intravenouschronic lymphocytic leukemiahematological disordersimmunoglobulinsinfectioninternational surveyIVIGmultiple myelomanon-Hodgkin lymphomaSCIGsecondary immunodeficiency

Identifiers

PMID30801785
PMCPMC6849602
OpenAlexW2916914646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.